Dr. Rosalind Watts

Dr Rosalind Watts is the Clinical Lead of the Imperial College Psilocybin for Depression trial, Psilodep 2. She trained as a clinical psychologist at UCL and practised psychotherapy for six years before joining the Imperial Psychedelic Research Group, led by Robin Carhart-Harris.

Rosalind designed the therapy protocol for Psilodep 2, worked as a lead guide alongside three other therapists and was running the day-to-day aspects of the trial. Rosalind developed a psychedelic therapy model she coined ACE, which stands for, ‘Accept, Connect, Embody’. Based on Acceptance and Commitment Therapy (ACT) and the ‘Psychological Flexibility Model’, she mapped the phenomenological journey that individuals under the influence of a psychedelic go through when they dive into their experience, extract the meaningful lessons to heal, and then integrate and embody them afterwards. Her qualitative research, exploring the perspectives of participants in several psychedelic research studies, gave rise to her interest in the common theme of ‘connectedness to Self, others, and the world’ as an essential aspect of psychedelic treatment. Rosalind co-hosts the monthly ‘Psychedelic Integration Group’ in London, alongside Michelle Baker Jones.